Th17/Treg ratio

Your immune system runs on a tug of war. One team of cells drives inflammation to attack threats. Another team shuts that inflammation down once the job is done.

This test measures the ratio between those two teams in your blood. When the inflammatory side pulls ahead, that shift has been reported across autoimmune and inflammatory diseases, and in some studies it tracks how active the disease is.

What This Ratio Actually Measures

The test reports the Th17/Treg ratio. That means T helper 17 cells divided by regulatory T cells. Both are types of CD4 T cell. CD4 T cells help coordinate the body's immune defenses.

Th17 cells drive inflammation and make IL-17, one of the immune system's inflammatory signals. Regulatory T cells are often called Tregs. They calm inflammation and help keep the immune system from attacking healthy tissue.

The published studies usually use peripheral blood mononuclear cells. Those are white blood cells isolated from a standard blood draw. A lab counts them by flow cytometry. Flow cytometry sorts and counts cells one by one using markers on their surface.

A higher Th17/Treg ratio means the inflammatory side is pulling ahead. But this is a research-stage marker. There is no standardized normal range, and different labs use different methods to count the cells, so a single number carries far less weight than it would for an established test like cholesterol. Its value comes from comparison against your own baseline and against your symptoms, not from crossing a fixed line.

Why the Balance Matters

In healthy people the two teams stay in rough proportion. When the inflammatory side expands or the regulatory side shrinks, autoimmune tissue damage becomes easier to sustain. That imbalance has been documented in the blood of people with lupus, rheumatoid arthritis, autoimmune thyroid disease, autoimmune liver disease, and HLA-B27-associated eye inflammation, all compared against healthy controls.

The shift can come from either direction. In lupus, the ratio climbs mainly because inflammatory Th17 cells rise. In idiopathic membranous nephropathy, a kidney disease, the ratio climbs instead because regulatory cells fall while Th17 cells stay flat. Same number, different cause. That is why the ratio needs context.

Autoimmune and Inflammatory Disease

In autoimmune conditions, a higher ratio often points to more active disease. In Hashimoto's thyroiditis, an autoimmune attack on the thyroid, the inflammatory cells roughly doubled while the regulatory cells fell, compared with healthy people. In rheumatoid arthritis, inflammatory cells outnumbered regulatory cells by about five to six to one, versus about one and a half to two to one in healthy subjects.

The link to disease activity is real but not uniform. In lupus, the ratio ran higher during active flares than during quiet periods. In rheumatoid arthritis the evidence is mixed: in the study cited here the ratio did not line up neatly with standard activity scores or with C-reactive protein, often checked as hs-CRP on preventive panels, while other studies have found the balance does track disease activity. The ratio reflects an immune process, not a diagnosis, so it complements disease-specific tests rather than replacing them.

Critical Illness and the Lungs

The sharpest outcome data come from intensive care. In a study of 79 adults with early ARDS, a severe form of lung failure, those with the highest ratios were far more likely to die within 28 days, and the ratio predicted death better than standard ICU severity scores. In a separate study of patients with sepsis, the ratio helped flag those who went on to develop acute kidney injury, especially when paired with a kidney-injury marker.

Sources: Yu et al. 2015 (Critical Care); Wen et al. 2025 (Frontiers in Immunology); Fang et al. 2022 (Frontiers in Endocrinology).

What this means for you: the ratio is not a routine health check. It earns its place when a specific inflammatory or immune process is already in play, where it can add a layer of information about how active or dangerous that process is.

A Reversal in Cancer

Here the ratio flips its meaning. In multiple myeloma, a blood cancer, a regulatory-dominant balance at diagnosis predicted the cancer returning sooner. In lymphoma, a similar regulatory-heavy pattern was tied to worse outcomes as well.

This looks like a contradiction. In autoimmune disease a high inflammatory tilt is bad, yet in cancer a strong regulatory tilt can also be bad. The reason is simple: this is not a good-number, bad-number marker. It is a picture of which way the immune system is leaning. When you need inflammation reined in, as in autoimmunity, a regulatory tilt helps. When you need the immune system fighting a tumor, that same regulatory tilt can suppress the attack and help the cancer. The healthy target depends on what your body is up against.

Heart Disease

Inflammation helps drive atherosclerosis, the buildup of plaque in arteries, and this ratio has been studied there too. In stable coronary patients, the regulatory side of the balance declined step by step as artery disease advanced. Another coronary heart disease study tied the ratio to other immune and vessel-risk markers, not to a stand-alone decision rule. The evidence is early and observational, so treat it as a signal to read alongside established heart markers, not as a heart test by itself.

Why One Reading Is Not Enough

For this marker, a trend beats a snapshot by a wide margin. There is no agreed reference range, and labs count these cells with different methods and cell-marker choices, so one lab's number does not translate cleanly to another's. The most reliable comparison is your own value over time, measured the same way at the same lab.

The blood ratio can also differ from what is happening inside an affected organ. In sarcoidosis, an inflammatory lung disease, the balance in lung fluid looked different from the balance in blood drawn from the same patients. A normal blood ratio does not rule out inflammation concentrated in a specific tissue.

When Results Can Be Misleading

A single reading can be thrown off by several things:

• Lab method: gating and cell-marker choices vary between labs, so two labs can report meaningfully different numbers from similar blood samples. Stick with one lab for comparisons.
• Sample handling: this test counts specialized immune cells, so timing between the blood draw and processing can matter more than it does for a chemistry test.
• Recent immune events: acute infection, surgery, vaccination, or a disease flare near the draw can push the balance toward the inflammatory side for reasons that may not reflect your usual baseline.
• Immune-modulating drugs: corticosteroids, statins, metformin, TNF inhibitors, sirolimus, and low-dose IL-2 can shift this balance. Your result may reflect a treated state, not your untreated state.
• Where the problem lives: the blood ratio may look fine while an organ-specific process is active, so a normal value does not clear you of tissue-level inflammation.